ArticleFrontiers in molecular biosciences2026
MicroRNA expression profile associated with coronary heart disease in patients with resistant arterial hypertension.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Resistant arterial hypertension (RAH) is associated with a high burden of cardiovascular complications, particularly coronary heart disease (CHD). MicroRNAs (miRNAs) are important regulators of cardiovascular remodeling and metabolic dysfunction; however, data regarding peripheral blood mononuclear cell (PBMC) miRNA expression in patients with RAH and concomitant CHD remain limited. This study aimed to evaluate PBMC miRNA expression profiles associated with CHD in patients with RAH and to explore their relationship with metabolic abnormalities. Methods: In this cross-sectional study, 115 patients with RAH were enrolled. PBMCs were isolated from peripheral blood and expression levels of selected microRNAs were quantified using TaqMan-based quantitative real-time PCR. Relative expression was calculated using the 2 Results: Compared with patients with isolated RAH, those with concomitant CHD exhibited significantly higher PBMC expression levels of miR-195 (p = 0.0148), miR-26b (p = 0.0166), miR-208 (p = 0.0435), and miR-320 (p = 0.0402). These microRNAs demonstrated strong positive intercorrelations, indicating a coordinated expression pattern. Within the CHD subgroup, expression levels of all four microRNAs were significantly higher in patients with type 2 diabetes (T2D) and positively correlated with glycated hemoglobin and body mass index. ROC analysis demonstrated modest discriminative ability for identifying T2D within the CHD subgroup, with the highest performance observed for miR-195 (AUC = 0.706). Conclusion: Patients with RAH and concomitant CHD exhibit a distinct PBMC microRNA expression profile characterized by increased expression of miR-195, miR-208, miR-26b, and miR-320. The association of these microRNAs with T2D and markers of metabolic dysfunction suggests that they may reflect the combined cardiovascular and metabolic disease burden in patients with advanced hypertension.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.